PMID: 2483189Nov 1, 1989Paper

[Anti-arrhythmic effect of cordaron in patients with unstable stenocardia and myocardial infarction].

Klinicheskaia meditsina
T E DobrotvorskaiaN L Matsueva

Abstract

Antiarrhythmic effect of cordaron in patients with unstable stenocardia (34) and transmural myocardial infarction (39) has been studied in various dose regimens. A dose of 400-600 mg/day was significantly effective in unstable angina pectoris, while in myocardial infarction a 600 mg/day dose failed to attenuate arrhythmia, i.e. the number and frequency of extra-systoles reduced insignificantly. In subacute disease a 200 mg/day cordaron could not prevent an increment of arrhythmia showing inadequacy of a standard scheme of the drug administration.

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.